## **Supporting Information**

## The Prediction of Aggregation Prone Regions of Therapeutic Proteins

Naresh Chennamsetty,  $^{\dagger}$  Vladimir Voynov,  $^{\dagger}$  Veysel Kayser,  $^{\dagger}$  Bernhard Helk,  $^{\ddagger}$  and Bernhardt L Trout  $^{*,\dagger}$ 

## **Contents:**

- 1. SEC-HPLC chromatogram for variant A7
- 2. SEC-HPLC chromatogram for variant A8

<sup>†</sup> Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts

<sup>&</sup>lt;sup>‡</sup> Novartis Pharma AG, CH-4002, Basel, Switzerland

 $<sup>*\</sup> Correspondence: trout@mit.edu$ 

## FIGURE CAPTIONS

**Figure S1.** The SEC-HPLC chromatogram for variant A7. (A) The full chromatogram. (B) The chromatogram is zoomed in to see the aggregate peak more clearly. We observe that the aggregate peaks are well separated from the monomer peaks.

**Figure S2.** The SEC-HPLC chromatogram for variant A8. (A) The full chromatogram. (B) The chromatogram is zoomed in to see the aggregate peak more clearly. We observe that the aggregate peaks are well separated from the monomer peaks.